Yes, it can. In a large clinical trial, RotaTeq demonstrated 98% efficacy against severe RGE and 74% efficacy against RGE of any severity through the first rotavirus season after vaccination. Also, infants who were vaccinated with RotaTeq were 94% less likely to visit an emergency room and 96% less likely to be hospitalized through the first 2 years after the third dose, due to the types of rotavirus targeted by the vaccine (G1, G2, G3, G4, and G9).